Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Shanghai, China-based Rona Therapeutics on Friday announced the completion of $35 million Series A+ financing. 22 July 2024
Biotechnology
Californian start-up Caribou Biosciences (Nasdaq: CRBU) has announced significant workforce reductions, cutting approximately 12% of its staff. 19 July 2024
Biotechnology
Swedish firm Enzymatica (STO: ENZY) will conduct a rights issue to raise approximately $12 million, with existing shareholders being given preferential rights. 18 July 2024
Pharmaceutical
A new research paper concluding that the use of Inpefa (sotagliflozin) for the treatment of patients hospitalized for heart failure (HF) and suffering from co- morbid diabetes leads to significant positive impact on provider health system financial outcomes. 18 July 2024
Biotechnology
The show is over for Aslan Pharmaceuticals, the immunology-focused biopharmaceutical company, as its financial troubles have led it to file for voluntary liquidation. 18 July 2024
Pharmaceutical
As the World Health Organization (WHO) calls for advancements to combat serious infections, one American firm is raising awareness about its work on nanoparticles. 17 July 2024
Biotechnology
Cardurion Pharmaceuticals, which is developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced a $260 million Series B financing. 16 July 2024
Biotechnology
AbbVie’s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. 16 July 2024
Pharmaceutical
Sionna Therapeutics today announced it has acquired exclusive worldwide rights to develop and commercialize multiple clinical-stage compounds through a license agreement with pharma major AbbVie. 16 July 2024
Biotechnology
German oncology start-up CatalYm has secured $150 million in a series D financing round to expand the development of its therapy, visugromab. 16 July 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze